Daily close, T-120 (2/24/25) through T+5. Run-up high $32.29 on 2/28/25, low $20.62 on 7/18/25 (T-120 to T-1). FDA decision 8/11/25. Historical price action, not a forecast.
Positioning before the decision
On Jul 28, 2025, 14 days before the decision date, at-the-money options priced a move of ±8.6% through Aug 15, 2025 (the first listed expiry after the decision; ATM implied volatility 96%). The stock closed +14.9% at the first close across the decision and +25.3% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Decision facts
FDA decision date2025-08-11
DrugIron Sucrose Injection
IndicationIron deficiency anemia (IDA) in patients with chronic kidney disease (CKD)
Yes. The FDA approved the application for Iron Sucrose Injection on August 11, 2025. The primary source is linked on this page.
What was Iron Sucrose Injection under FDA review for?
The application covered Iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). The FDA approved the application on August 11, 2025.
How did AMPH stock react to the FDA decision?
On the decision day AMPH moved +14.9%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.